For over three decades, CEI has advocated health care reforms that put more power in the hands of consumers to choose their health providers, treatment protocols, and scope of insurance coverage. We have advocated reform of the Food and Drug Administration’s drug and device approval process to allow for greater flexibility and patient choice. And in 2013, CEI organized the court challenges to Obamacare’s exchange subsidies that concluded with the Supreme Court’s King v. Burwell decision.
Healthcare Issue Areas
Featured Posts
Blog
What Trump’s vaccine executive order actually does
Yesterday, President Trump signed an executive order directing federal health agencies to revise childhood vaccine recommendations, reducing the number of vaccines recommended for…
Blog
Trump administration decision highlights disastrous Part D redesign
The Trump administration recently announced the end of a demonstration project that was pulled together by the Biden administration as the Inflation Reduction…
Blog
Fauci’s lasting legacy will be the damage he did to science and government
Anthony Fauci isn’t faring well in the court of public opinion. His recently divulged “diary” and subsequent July 29 appearance before the Senate Homeland…
Search Posts
Op-Eds
Often Wrong, Never in Doubt
Times have changed. Two years ago, tennis great Novak Djokovic could not play in the U.S. Open tournament. It was not because he had…
Blog
Can AI thrive in health care’s HIPAA-shaped box?
Innovation continues to transform health care, enabling us to live longer and healthier lives. And now artificial intelligence (AI) is poised to supercharge…
The Wall Street Journal
The FTC Goes Evidence-Free
Through three years of Lina Khan’s leadership, the Federal Trade Commission has suffered an unprecedented streak of high-profile court defeats. That’s because the agency regularly…
Blog
This week in ridiculous regulations: Blood donors and paper marketing
Donald Trump survived an assassination attempt. The Republicans held their convention in Milwaukee. Sen. Robert Menendez (D-NJ) was convicted on bribery charges and resigned,…
Blog
Missing the economists in FTC’s latest PBM study
The Federal Trade Commission (FTC) released its not-so-objectively titled interim report on Pharmacy Benefit Managers (PBMs): Pharmacy Benefit Managers: The Powerful Middlemen Inflating…
News Release
New FTC study on drug costs fails to conduct empirical analysis of market conditions
The Federal Trade Commission (FTC) release a new study today claiming Pharmacy Benefit Managers (PBMs) are responsible for higher drug costs. FTC Commissioner Melissa…